Exelixis Inc
EXEL: XNAS (USA)
Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
---|---|---|---|
$71.70 | Krfv | Mjnkwxmn |
No-Moat Exelixis Faces Cabozantinib Patent Losses by 2026; FVE of $18.90, Shares Fairly Valued
After taking a fresh look at Exelixis, we’ve relaunched coverage with a fair value estimate of $18.90 per share, a no-moat rating, and a stable moat trend. The stock is currently trading in 3-star territory. Exelixis is a biopharmaceutical firm focused on the treatment of cancer. Its lead molecule, cabozantinib, is the active ingredient in two of Exelixis’ three approved drugs: Cabometyx and Cometriq. Cabometyx treats kidney cancer and second-line liver cancer and Cometriq treats medullary thyroid cancer. Exelixis’ third approved drug, Cotellic, treats melanoma.